Viropharma Inc: (NASD: VPHM)
$26.10
0.24 (0.93%)
Volume 1,037,176
May 22 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 25.84 - 26.73 |
| 52wk Low - High | 19.44 - 31.36 |
| Previous Close | 25.86 |
| Avg. Volume | 667,848 |
| Industry | MED-DRUGS |
| Market Cap | 1.69 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.55 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.64 |
| Quarterly Earnings ESP |
-50.00% |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
108 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.64 |
| Current Quarter Estimate | 0.02 |
| Most Accurate Estimate | 0.01 |
| Earnings ESP |
-50.00% |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | 0.18 |
| Expected Earnings Growth | 11.75% |
Company Description
ViroPharma Incorporated is an international biopharmaceutical company focused on developing and commercializing products for physician specialists or in hospital settings. The Company's marketed products include Cinryze TM and Vancocin?. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema (HAE), also known as C1 inhibitor (C1-INH) deficiency, a rare, severely debilitating, life-threatening genetic disorder. Vancocin is a potent antibiotic to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI), or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile. The Company sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. ViroPharma Incorporated is headquartered in Exton, Pennsylvania.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.02 | 0.06 | -0.64 | 0.76 |
| Number of Estimates | 11 | 11 | 11 | 11 |
| Low Estimate | -0.04 | 0.03 | -0.91 | 0.18 |
| High Estimate | 0.07 | 0.10 | 0.70 | NA |
| Year Ago EPS | 0.06 | 0.02 | 0.29 | -0.64 |
| EPS Growth | -62.12% | 213.64% | -320.06% | 218.52% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| VIROPHARMA | VPHM | 25.86 | |
|
| JAZZ PHARMACEUT | JAZZ | 60.00 | |
|
| SALIX PHARM-LTD | SLXP | 59.33 | |
|
| SANTARUS INC | SNTS | 22.30 | |
|
| USANA HLTH SCI | USNA | 67.95 | |
|
| BIOCRYST PHARMA | BCRX | 1.70 | |
|
| CATALYST PHARMA | CPRX | 0.91 | |
|
| CELL THERAPEUT | CTIC | 1.32 | |
|
| CUBIST PHARM | CBST | 55.46 | |
|
| ELAN CP PLC ADR | ELN | 12.07 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
ViroPharma Reports Loss in 1Q
May 02, 2013
The Zacks Analyst Blog Highlights: AT&T, Optimer Pharmaceuticals, ViroPharma, Astellas Pharma and Incyte
May 02, 2013
Optimer's Dificid Cleared Down Under
May 01, 2013
Pipeline Progresses at ViroPharma
Apr 23, 2013
Shire Buys Premacure
Mar 14, 2013
ViroPharma Tops on All Fronts
Feb 28, 2013
Data on ViroPharma's Cinryze
Jan 18, 2013
Upbeat 2013 from ViroPharma
Jan 08, 2013
Financials
| EPS TTM | 0.18 |
| Sales | 428 |
| Net Income | -77 |
| Price/Earnings | 143.67 |
| Price/Book | 2.41 |
| Price/Cash Flow | 29.31 |
| Price/Sales | 4.22 |
News
Relatively Good Performance Detected in Shares of Warner Chilcott in the Pharmaceuticals Industry (WCRX, MRK, JAZZ, SNY, VPHM) - Financial News Network Online - News Corner
May 22, 2013
Shares of Viropharma Receive a Boost, Up 2.3% - Financial News Network Online - Market Movers
May 21, 2013
ViroPharma Proudly Supports HAE Day :-) 2013 - Pr Newswire Europe
May 16, 2013
ViroPharma reports net loss for Q1, provides outlook for 2013 - Datamonitor
May 15, 2013
Shares of Viropharma Receive a Boost, Up 2.3% - Financial News Network Online - Market Movers
May 13, 2013
Filings & Reports: ViroPharma - Investrend
May 11, 2013
Shares of Viropharma Receive a Boost, Up 1.4% - Financial News Network Online - Market Movers
May 9, 2013
ViroPharma To Participate In Two May Healthcare Investor Conferences - Pr Newswire
May 9, 2013
Broker Recommendations
| Current ABR | 1.21 |
| ABR (Last Week) | 1.21 |
| # of recs in ABR | 14 |
| Average Target Price | 33.92 |
| Industry Rank by ABR | 108 out of 265 |
| Rank in Industry | 16 out of 93 |
